[1] Zhang X, Zhou D, Song S, et al.Efficacy and safety of long-term dual antiplatelet therapy: A systematic review and meta-analysis[J]. Clin Appl Thromb Hemost, 2024, 30: 10760296241244772.
[2] Martinez Bravo G, Annarapu G, Carmona E, et al.Platelets in thrombosis and atherosclerosis: A double-edged sword[J]. Am J Pathol, 2024, 194(9): 1608-1621.
[3] Asada Y, Yamashita A, Sato Y, et al.Pathophysiology of atherothrombosis: Mechanisms of thrombus formation on disrupted atherosclerotic plaques[J]. Pathol Int, 2020, 70(6): 309-322.
[4] Chen HS, Cui Y, Wang XH, et al.Clopidogrel plus aspirin vs aspirin alone in patients with acute mild to moderate stroke: The ATAMIS Randomized Clinical Trial[J]. JAMA neurology, 2024, 81(5), 450-460.
[5] Ge Z, Kan J, Gao X, et al.Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomised, placebo-controlled, double-blind clinical trial[J]. Lancet (London, England), 2024, 403(10439): 1854.
[6] Gragnano F, Cao D, Pirondini L, et al.P2Y12 Inhibitor or Aspirin monotherapy for secondary prevention of coronary events[J]. J Am Coll Cardiol, 2023, 82(2): 89-105.
[7] Rgeeb AN, Alsalkh HA, Radhi AK, et al.Effect of intravenous abciximab on coronary flow improvement after re-vascularization in primary coronary intervention and short term impact[J]. Med Arch, 2020, 74(4): 265-269.
[8] Revilla-Martí P, Linares-Vicente JA, Martínez Labuena A, et al.Efficacy and safety of abciximab versus tirofiban in addition to ticagrelor in STEMI patients undergoing primary percutaneous intervention[J]. Platelets, 2022, 33(2): 265-272.
[9] Du Y, Li Y, Duan Z, et al.The efficacy and safety of intravenous tirofiban in the treatment of acute ischemic stroke patients with early neurological deterioration[J]. J Clin Pharm Ther, 2022, 47(12): 2350-2359.
[10] Kristensen AMD, Pareek M, Kragholm KH, et al.Long-term aspirin adherence following myocardial infarction and risk of cardiovascular events[J]. Eur Heart J Qual Care Clin Outcomes, 2024, 10(7): 612-622.
[11] Lacaze P, Bakshi A, Riaz M, et al.Aspirin for Primary Prevention of Cardiovascular Events in Relation to Lipoprotein(a) Genotypes[J]. J Am Coll Cardiol, 2022, 80(14): 1287-1298.
[12] Patrono C.Low-dose aspirin for the prevention of atherosclerotic cardiovascular disease[J]. Eur Heart J, 2024, 45(27): 2362-2376.
[13] Jones WS, Mulder H, Wruck LM, et al.Comparative Effectiveness of aspirin dosing in cardiovascular disease[J]. N Engl J Med, 2021, 384(21): 1981-1990.
[14] Fu X, Lei T, Chen C,et al.Construction and study of blood purification membrane modified with PDE inhibitor: Investigation of antiplatelet activity and hemocompatibility[J]. Colloids Surf B Biointerfaces, 2024, 234: 113725.
[15] Coenen DM, Heinzmann ACA, Oggero S, et al.Inhibition of phosphodiesterase 3A by cilostazol dampens proinflammatory platelet functions[J]. Cells, 2021, 10(8): 1998.
[16] Degjoni A, Campolo F, Stefanini L, et al.The NO/cGMP/PKG pathway in platelets: The therapeutic potential of PDE5 inhibitors in platelet disorders[J]. J Thromb Haemost, 2022, 20(11): 2465-2474.
[17] Navarro S, Stegner D, Nieswandt B, et al.Temporal roles of platelet and coagulation pathways in collagen- and tissue factor-induced thrombus formation[J]. Int J Mol Sci, 2021, 23(1): 358.
[18] Scherlinger M, Richez C, Tsokos GC, Boilard E, Blanco P.The role of platelets in immune-mediated inflammatory diseases[J]. Nat Rev Immunol, 2023, 23(8): 495-510. |
